[Effects of gadobenate dimeglumine on MRI of mouse liver metastasis model constructed by orthotopic transplantation of highly metastatic murine colon carcinoma (C38-OT7): comparison with gadopentetate dimeglumine].
Twelve mice with metastatic liver tumors were divided into two groups of six, with one group administered contrast medium at 0.1 mmol/kg, and the other at 0.2 mmol/kg. Contrast medium, gadobenate dimeglumine (GD) or gadopentetate dimeglumine (GP), was administered at 0.1 or 0.2 mmol/kg via the tail vein to each animal in each group. Using a Signa Horizon 1.5-Tesla MRI unit, spin-echo transverse and coronal T1-weighted sections were obtained every 15 minutes until 2 hours after administration. The numbers of liver tumors detected on films were counted before and after the administration of contrast medium, and the liver/tumor contrast-to-noise ratio (CNR) was calculated. After the completion of MRI, livers were removed, and the number of metastatic nodules on the liver surface were counted as the number of tumors. Liver/tumor CNR rose after administration in both of the GD groups. In the GP group, liver/tumor CNR remained almost constant throughout the observation period. Relative to the number of tumors detected at optical microscopy, approximately 80% and 100% of tumors were detected at MRI after the administration of GD at 0.1 and 0.2 mmol/kg, respectively. On the other hand, approximately similar numbers of tumors were detected at MRI before and after the administration of GP. These results suggest that GD administered by intravenous injection was transported promptly to the liver, increased liver/tumor CNR, and enhanced detection performance for metastatic liver tumor.